



Published in final edited form as:

*J Prev Alzheimers Dis.* 2018 ; 5(4): 245–252. doi:10.14283/jpad.2018.35.

## Clinical Application of APOE in Alzheimer’s Prevention: A Precision Medicine Approach

C.L. Berkowitz<sup>1</sup>, L. Mosconi<sup>2</sup>, A. Rahman<sup>2</sup>, O. Scheyer<sup>2</sup>, H. Hristov<sup>2</sup>, and R.S. Isaacson<sup>2</sup>

<sup>1</sup>Weill Cornell Medical College, New York, NY, 10021, USA

<sup>2</sup>Department of Neurology, Weill Cornell Medicine, New York, NY, 10021, USA

### Abstract

Population-attributable risk models estimate that up to one-third of Alzheimer’s disease (AD) cases may be preventable through risk factor modification. The field of AD prevention has largely focused on addressing these factors through universal risk reduction strategies for the general population. However, targeting these strategies in a clinical precision medicine fashion, including the use of genetic risk factors, allows for potentially greater impact on AD risk reduction. Apolipoprotein E (APOE), and specifically the APOE  $\epsilon 4$  variant, is one of the most well-established genetic influencers on late-onset AD risk. In this review, we evaluate the impact of APOE  $\epsilon 4$  carrier status on AD prevention interventions, including lifestyle, nutrigenomic, pharmacogenomic, AD comorbidities, and other biological and behavioral considerations. Using a clinical precision medicine strategy that incorporates APOE  $\epsilon 4$  carrier status may provide a highly targeted and distinct approach to AD prevention with greater potential for success.

### Keywords

Alzheimer’s disease; Alzheimer’s disease prevention; apolipoprotein  $\epsilon 4$ ; APOE; clinical precision medicine

### Introduction

Alzheimer’s disease (AD) affects more than 5.5 million people in the United States, and is estimated to affect as many as 24 million people worldwide (1). While the prevalence of AD increases 15-fold between the ages of 65 to 85, research has shown that the disease starts to develop in the brain decades before clinical symptoms become apparent (2). Recent epidemiological studies have shown that up to one-third of dementia cases may be preventable through risk factor modification, including changes in diet, activity level, and

---

*Corresponding Author:* Richard S. Isaacson, MD, Department of Neurology, Weill Cornell Medicine and New York-Presbyterian, 428 East 72nd St, Suite 500, Room 407, New York, NY, 10021; Tel: (212) 746-3645, rii9004@med.cornell.edu.

*Disclosures:* R.S.I. has served as a consultant for Neurotrack, and 23 and Me; other authors declare no conflict of interest. The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

*Conflict of interest:* Dr. Isaacson has served as a scientific advisor for Neurotrack and 23 and Me. All other authors declare no conflict of interest. The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

*Ethical standards:* The clinical and education research trials described have been reviewed and approved by the IRB.

management of comorbidities such as diabetes, hypertension, and hyperlipidemia (3). These patient-specific lifestyle, behavioral, and treatment modifications, in addition to family history and genetic risk factor assessment, can be used to provide a highly targeted and distinct approach to AD prevention.

While the field of AD prevention continues to evolve, many interventions are based on universal risk-reduction strategies for the general population rather than a clinical precision medicine approach that incorporates individualized risk factors such as genetics. Targeting AD prevention strategies in such a way is important because it allows for optimal risk reduction by addressing risk factors for a particular individual. In the following discussion, we review examples of a clinical precision medicine AD prevention strategy, that factors in the most well-established genetic influencer on late-onset AD risk, apolipoprotein E (APOE) (4), and which may impact the effectiveness of various AD prevention interventions. We begin with an introduction to the APOE gene, followed by a discussion of the literature linking the specific APOE  $\epsilon$ 4 polymorphism to increased risk of AD. We then review the literature investigating whether APOE  $\epsilon$ 4 has been shown to modify the effectiveness of various prevention interventions for AD. From a practical clinical perspective, considering that APOE is available via direct-to-consumer testing, and also readily available to order by clinicians, its application in routine clinical care should be further explored as its use may lead to more specialized and effective prevention strategies to come.

## APOE and AD Risk

APOE is a gene that codes for the apolipoprotein E protein, which is important in the transport and metabolism of lipids (5). The three major alleles of the APOE gene are  $\epsilon$ 2,  $\epsilon$ 3, and  $\epsilon$ 4. APOE  $\epsilon$ 4 carriers are at increased risk for developing AD and increased risk for developing the disease at an earlier age (6), while APOE  $\epsilon$ 2 carriers are at decreased risk for developing the disease (7). Furthermore, studies have shown that individuals with two copies of the  $\epsilon$ 4 allele are at even greater risk, and the odds ratios for developing AD based on APOE is 5 times greater in APOE  $\epsilon$ 4 homozygotes compared to heterozygotes (8). Imaging studies have further supported these findings by demonstrating that APOE  $\epsilon$ 4 carriers have higher levels of brain amyloid- $\beta$  ( $A\beta$ ) and lower levels of CSF  $A\beta$ 42 compared to non-carriers, findings that are associated with AD pathology (9–12).

With such a strong potential for the APOE  $\epsilon$ 4 variant to affect the development of AD, and given that its frequency in the general population is estimated to range from 0.09 to 0.30 (8, 13), it is important to consider AD prevention strategies in relation to  $\epsilon$ 4 carrier status. Tailoring AD prevention strategies to  $\epsilon$ 4 carrier status in such a way is one example of how the field of AD prevention can take further steps towards more precision-based care for its patients.

## Utility of APOE in the Clinical Practice of AD Prevention: Lifestyle, Nutrigenomic, Pharmacogenomic, and AD Comorbidity Considerations

In this section, we discuss research incorporating APOE  $\epsilon$ 4 carrier status into strategies for AD prevention, including considerations related to lifestyle, nutrigenomics,

pharmacogenomics, AD comorbidities, and other biological and behavioral factors that may be impacted by  $\epsilon 4$  carrier status.

## Multi-Modal Lifestyle Considerations

Some clinical trials have demonstrated that multimodal interventions aimed at reducing AD risk, including nutrition, physical activity, cognitive engagement, and management of comorbidities improved cognitive functioning in non-impaired individuals at risk for AD (14, 15). A subgroup analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) trial showed that there was no significant difference between the effects of lifestyle modifications on cognitive function in APOE  $\epsilon 4$  carriers versus non-carriers (16). However, within-group analysis by  $\epsilon 4$  carrier status demonstrated that there was greater improvement in certain measures of cognitive function in treatment versus control groups for  $\epsilon 4$  carriers compared to non-carriers. These findings suggest that  $\epsilon 4$  carriers may respond differently than non-carriers to certain interventions, and examination of more specialized prevention strategies based on  $\epsilon 4$  carrier status is warranted.

### Physical Activity

Physical activity is a critical aspect of AD prevention (12, 17–19). A systematic review of 16 prospective studies concluded that physical activity decreased the risk of developing AD by 45% (19). Several studies have further demonstrated a difference in response to physical activity in APOE  $\epsilon 4$  carriers versus non-carriers (20, 21). For example, sedentary  $\epsilon 4$  non-carriers had an odds ratio (OR) for AD of 1.77 compared to physically active non-carriers, whereas physically active  $\epsilon 4$  carriers had an OR of 2.30 and sedentary  $\epsilon 4$  carriers had an OR of 5.53 (20). Another study demonstrated that aerobic activity was associated with greater cognitive performance for  $\epsilon 4$  carriers compared to non-carriers (21). Neuroimaging studies have further demonstrated that  $\epsilon 4$  carrier status exacerbates the effect of a sedentary lifestyle on AD pathology in cognitively healthy individuals (12, 22). One study demonstrated that sedentary individuals who were  $\epsilon 4$  carriers had significantly higher levels of brain A $\beta$  and lower levels of CSF A $\beta 42$  compared to sedentary non-carriers, findings associated with AD pathology (12). Another study showed that the least physically active  $\epsilon 4$  carriers had significantly higher levels of brain A $\beta$  than the least physically active non-carriers, whereas the most physically active individuals had similar levels of brain A $\beta$  regardless of  $\epsilon 4$  carrier status (22). These findings have important implications for physical activity recommendations and suggest that increasing physical activity, while important for all AD prevention patients, may have more pronounced effects in  $\epsilon 4$  carriers compared to non-carriers. The findings also suggest that physical activity may prevent A $\beta$  accumulation that occurs in the brains of  $\epsilon 4$  carriers before clinical symptoms of AD even become apparent.

Physical activity may not only prevent cognitive decline, but may also improve cognitive function. For example, one neuroimaging study showed that physical activity improved semantic memory processing for  $\epsilon 4$  carriers as measured by fMRI brain imaging (23). While another RCT found that non-carriers had greater improvement in cognitive function in response to physical activity, this study was performed in patients already experiencing

subjective cognitive complaints at baseline (24). This further suggests that physical activity may be most effective for  $\epsilon 4$  carriers during a critical window of AD prevention before clinical symptoms begin to develop. Overall, the current evidence demonstrates that exercise is a critical intervention, especially for non-impaired  $\epsilon 4$  carriers. Specialized, more effective prevention strategies for  $\epsilon 4$  carriers may be possible in the future but will require additional investigation into the type and intensity of physical activity necessary to optimize AD risk reduction for this population.

### **Tobacco Use**

A meta-analysis indicated that there was conflicting evidence about the association between tobacco use and risk of AD (25). When accounting for APOE  $\epsilon 4$  carrier status several studies have found that  $\epsilon 4$  carriers have a greater risk of AD associated with tobacco use than non-carriers (20, 26), although some have found no association (27). In one study, smokers who were  $\epsilon 4$  carriers had lower auditory-verbal learning and memory scores compared to smokers who were non-carriers and compared to non-smokers regardless of  $\epsilon 4$  carrier status (26). The study further showed that  $\epsilon 4$  carriers who were smokers had more brain A $\beta$  deposition compared to carriers who were non-smokers as well as non-carriers regardless of smoking history. Overall, these findings demonstrate that  $\epsilon 4$  carrier status may exacerbate the effects of smoking on the development of AD pathology and cognitive impairment. While smoking cessation is an important preventative health strategy for numerous health reasons, it may be especially important for  $\epsilon 4$  carriers for AD prevention as well.

### **Alcohol Use**

Light-to-moderate alcohol consumption has been associated with a decreased risk of AD (28), whereas heavy alcohol consumption has been associated with an increased risk (29). However, this relationship may not apply to  $\epsilon 4$  carriers. Up to three servings of wine per day has been associated with a lower risk of AD for  $\epsilon 4$  non-carriers (30), while consumption of any amount of alcohol may increase the risk of AD for  $\epsilon 4$  carriers (20, 31, 32). In one study, both light (1-6 drinks per week) and moderate (7-14 drinks per week) alcohol consumption was associated with improvement in learning and memory for  $\epsilon 4$  non-carriers, but with a decline in learning and memory for  $\epsilon 4$  carriers (31). Similarly, in other studies  $\epsilon 4$  carriers who consumed alcohol one or more times per month had a higher risk of AD than those who never consumed alcohol (20) and the risk of AD for  $\epsilon 4$  carriers increased with increasing amounts of alcohol consumption (32). While another study showed that alcohol consumption was associated with a decreased risk of AD for  $\epsilon 4$  carrier women, this study was conducted retrospectively through interviews with relatives and only had  $\epsilon 4$  carrier status for 64% of cases and for none of the controls (27). Overall, the majority of evidence suggests that alcohol consumption for AD prevention may need to be tailored to  $\epsilon 4$  carrier status. Whereas light-to-moderate alcohol consumption may be beneficial for non-carriers for AD prevention, decreasing alcohol intake or abstaining from alcohol may be beneficial for carriers.

## Cognitive Engagement

Participating in cognitively engaging activities such as games, crafts, music, computer usage, and social activities has been associated with a decreased risk of incident Mild Cognitive Impairment (MCI) (33) and AD (34, 35). Some studies suggest that this protective effect may be particularly significant for  $\epsilon 4$  carriers (36, 37). Among others, one study showed that engaging in recreational activities or hobbies was associated with a significantly reduced risk of cognitive decline, and this effect was more pronounced for  $\epsilon 4$  carriers (36). Consistent with these findings, a neuroimaging study showed A $\beta$  deposition was decreased in  $\epsilon 4$  carriers who had greater lifetime cognitive activity (38). However, other studies suggest that non-carriers benefit more from cognitive engagement (33, 39). For example, in one study  $\epsilon 4$  non-carriers who engaged in cognitively stimulating activities had the lowest risk of MCI (hazard ratio [HR] of 0.73), while  $\epsilon 4$  carriers who did not engage in these activities had the highest risk (HR of 1.74) (33). Another study showed that engaging in cognitively stimulating activities was not associated with a reduced risk of cognitive decline in  $\epsilon 4$  carriers, although this study had a smaller sample size and follow-up was only up to 18 months (39). Overall, the evidence suggests that increasing amounts of cognitive engagement may decrease the risk of AD, although it is unclear whether these activities have greater benefits for  $\epsilon 4$  carriers or non-carriers. It is possible that carriers and non-carriers may respond differently to specific types of cognitive engagement. It is also possible that individuals with greater cognitive reserve elect to participate in more cognitively stimulating activities. Therefore, further research is required to explore the impact of cognitive engagement on AD risk in both carriers and non-carriers, as well as to explore the specific types of cognitive activities that may offer the greatest impact based on carrier status.

## Nutrigenomic Considerations

### Diet

The Mediterranean diet (MeDi), which generally emphasizes vegetables, legumes, monounsaturated and polyunsaturated fats, moderate amounts of fish, poultry and alcohol and limited amounts of dairy and red meat (40), has been associated with a decreased risk of AD (40, 41). For example, one study showed that MeDi adherence reduced the risk of cognitive impairment by 33% (41). Neuroimaging findings have also supported the benefits of MeDi adherence for AD prevention. One study demonstrated that non-impaired subjects with higher MeDi adherence exhibited greater cortical thickness in AD-affected brain regions compared to those with lower adherence (40). Studies also suggest that MeDi adherence has more importance for  $\epsilon 4$  non-carriers compared to carriers for the purposes of AD prevention (40, 42). Among those with high MeDi adherence,  $\epsilon 4$  non-carriers had greater cortical thickness in AD-affected brain regions than carriers, whereas there was no difference between carriers and non-carriers among those with low MeDi adherence (40). Another study demonstrated that MeDi adherence was associated with better performance on the clock drawing test, a measure of executive functioning and spatial reasoning, for  $\epsilon 4$  non-carriers but not for  $\epsilon 4$  carriers (42). These findings present both anatomical and clinical evidence that MeDi adherence may have greater AD preventative effects for  $\epsilon 4$  non-carriers. However, a recent study demonstrated that there was no association between MeDi adherence and A $\beta$  deposition in healthy individuals regardless of  $\epsilon 4$  carrier status (43). This

raises the question of whether the association between MeDi adherence and cognitive function and cortical thickness seen in prior studies is due to another mechanism unrelated to decreasing A $\beta$  deposition. Therefore, additional research is warranted to confirm this finding and further explore the benefits of MeDi adherence for  $\epsilon$ 4 non-carriers.

In addition to MeDi adherence, dietary saturated fatty acid (SFA) content has also been examined for AD risk and prevention. Diets high in SFAs have been associated with lower cognitive function and increased risk of incident MCI (44). Some studies also suggest that high SFA diets are associated with a greater risk of AD for  $\epsilon$ 4 carriers compared to non-carriers (20, 45). For example, one study showed that  $\epsilon$ 4 carriers who consumed a diet high in SFAs had a 7-fold increased risk for AD compared to non-carriers (20). However, another recent study demonstrated conflicting results regarding the effect of a low SFA diet for  $\epsilon$ 4 carriers. In this study, non-impaired  $\epsilon$ 4 carriers who consumed a diet high in SFAs (50% total fat, 25% SFA) with a high glycemic index (GI > 70) as opposed to a diet low in SFA (25% total fat, 7% SFA) with a low glycemic index (GI < 70) exhibited greater improvement in cognitive function, whereas non-carriers exhibited decreased cognitive function on the high SFA and high GI diet (46). A RCT is underway that aims to further explore the impact of a high SFA and high GI diet on cognitive function for  $\epsilon$ 4 carriers and non-carriers (47). The results of this trial, which is scheduled to be completed in 2020, will potentially offer more clarity on whether a high or low SFA diet may offer the most benefit for AD prevention. It should be noted, however, that this study investigates the impact of both high SFA and high GI together so it may not be possible to discern the impact of either dietary intervention alone on cognitive function. Future studies should assess the impact of high SFA and high GI diets separately to explore their individual impacts on cognitive function and AD risk reduction.

### **n-3 Polyunsaturated Fatty Acids**

Optimizing levels of the n-3 polyunsaturated fatty acids (n-3 PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is another important consideration for AD prevention (48, 49). Three recent RCTs support the use of high-dose DHA supplementation in non-impaired  $\epsilon$ 4 carriers for AD prevention (49). One RCT showed that male  $\epsilon$ 4 carriers who received 1.16g/day of DHA exhibited greater improvement in memory reaction time compared to non-carriers (50). Another RCT showed that  $\epsilon$ 4 carriers who received 800 mg of DHA for 3 years exhibited improvement in composite scores (49, 51). A third RCT showed that  $\epsilon$ 4 carriers receiving either low-dose (0.4g/day) or high dose (1.8g/day) EPA and DHA supplementation for 26 weeks improved in attentional measures of cognition (52). While other studies have found that non-carriers have greater improvement in response to fish consumption or DHA supplementation, these subjects already had mild to moderate AD or subjective memory complaints and therefore these  $\epsilon$ 4 carriers may already be outside a possible critical window for prevention (53–55).

Overall, these results suggest that n-3 PUFAs may have the greatest AD preventive effect for non-impaired  $\epsilon$ 4 carriers and may have less of a therapeutic effect after clinical symptoms of AD begin to appear. However, another important consideration is the impact of n-3 PUFA supplementation on serum LDL cholesterol. One review showed that n-3 PUFA

supplementation resulted in higher serum LDL and the effects were greater in  $\epsilon 4$  carriers compared to non-carriers (56). Another RCT showed that DHA supplementation (3.7g/day) resulted in a non-significant 10% increase in LDL for  $\epsilon 4$  carriers compared to a non-significant 4% reduction in LDL for non-carriers (57). While not statistically significant, this trend towards elevated LDL in  $\epsilon 4$  carriers following DHA supplementation requires more investigation as elevated LDL is another risk factor for AD. Therefore, further research is necessary to define the precise relationship between APOE  $\epsilon 4$  and n-3 PUFA supplementation, as well as to determine the most effective dose or formulation to maximize AD risk reduction.

## Vitamin D

A recent systematic review and meta-analysis showed that the risk of cognitive impairment was more than doubled in those with low vitamin D levels, ranging from less than 25-50 nmol/l depending on the study (58). However, analysis of the 1958 British birth cohort of over 18,000 individuals demonstrated that both low (<25 nmol/l) and high ( $\geq 75$  nmol/l) vitamin D levels were associated with lower cognitive functioning (59). This non-linear association was further described in a recent study investigating the impact of vitamin D concentrations and APOE  $\epsilon 4$  carrier status on cognitive function. In this study, researchers demonstrated that  $\epsilon 4$  homozygotes with high vitamin D concentrations had higher cognitive functioning and those with low vitamin D concentrations had lower cognitive functioning (60). However,  $\epsilon 4$  heterozygotes and non-carriers with high vitamin D concentrations had lower cognitive functioning. Along with the previous study, these findings suggest that there might be an ideal range of vitamin D that could vary based on individual characteristics, such as  $\epsilon 4$  carrier status, and that vitamin D supplementation may be preferential for APOE  $\epsilon 4$  homozygotes. However, additional research is required to define the precise range of vitamin D for optimal cognitive functioning in  $\epsilon 4$  carriers and non-carriers, as well as to determine whether vitamin D supplementation improves cognitive function in those with deficiency.

## Pharmacogenomic Considerations

Few pharmacologic AD prevention studies to date have factored in APOE  $\epsilon 4$  carrier status into their trials. One such study showed that individuals taking antihypertensive medication at baseline had a lower risk of AD, and that the risk was decreased to a greater extent in  $\epsilon 4$  carriers compared to non-carriers (61). NSAIDs have also been associated with a decreased risk of AD in  $\epsilon 4$  carriers (62, 63). However, the ADAPT trial, which randomized non-impaired subjects to receive naproxen, celecoxib, or placebo, paradoxically showed worse cognitive scores in the naproxen and celecoxib groups compared to placebo at two years and was stopped prematurely due to an increased risk of negative outcomes (64). In addition, the TOMORROW Phase III AD prevention trial was recently terminated as the diabetes drug pioglitazone was not found to prevent transition from normal cognition to MCI due to AD compared to placebo regardless of APOE  $\epsilon 4$  carrier status (65).

New clinical trials, such as the Alzheimer's Prevention Initiative Generation Study, will hopefully clarify the importance of APOE  $\epsilon 4$  carrier status on new potential drug targets

(66). The Generation Study consists of two ongoing longitudinal trials of APOE  $\epsilon$ 4 carriers with the goal of determining the effectiveness of new medications on preventing the development of AD in preclinical AD patients. The results of these trials will help to characterize the importance of targeting pharmaceutical-based interventions to at risk populations and can ultimately advance the field of clinical precision medicine for AD prevention.

## AD Comorbidity Considerations

Risk factors for cardiovascular disease, including hypertension, diabetes mellitus, and hyperlipidemia, have also been shown to be risk factors for AD and cognitive decline (67). The association between these risk factors and APOE  $\epsilon$ 4 carrier status is discussed below.

### Hypertension

While the literature is inconsistent about the risk of AD associated with hypertension in individuals over age 60 (68–71), studies indicate that elevated systolic blood pressure (SBP) ( $\geq 160$  mm Hg) in midlife is associated with an increased risk of eventual AD (68, 72, 73). Hypertension has also been associated with an increased risk of AD and cognitive decline in APOE  $\epsilon$ 4 carriers compared to non-carriers (74, 75). One study investigated the longitudinal impact of high SBP and APOE  $\epsilon$ 4 carrier status on cognitive function in non-impaired individuals age 45-68 over a 26-year time frame (74). Compared to non-carriers with normal SBP ( $<160$  mm Hg), the relative risk (RR) for poor cognitive function for  $\epsilon$ 4 carriers with normal SBP was 1.3, for non-carriers with high SBP was 2.6, and for carriers with high SBP was 13.0 (74). The authors further showed that treatment of hypertension reduced the risk for carriers with high SBP from 13.0 to 1.9. In addition, another study showed that elevated SBP ( $\geq 140$  mm Hg) or diastolic blood pressure (DBP) ( $\geq 90$  mm Hg) exacerbated A $\beta$  deposition in cognitively healthy individuals who were APOE  $\epsilon$ 4 carriers aged 47 to 89 years old (75). Therefore, adequate management of blood pressure may be particularly important for AD prevention for  $\epsilon$ 4 carriers, although additional research is necessary to determine optimal blood pressure ranges for AD prevention for  $\epsilon$ 4 carriers in younger and older cohorts.

### Diabetes Mellitus

Management of Type 2 Diabetes Mellitus (T2DM) is also an important AD prevention strategy (76). A meta-analysis reported that four out of five studies evaluating the association between T2DM and APOE  $\epsilon$ 4 carrier status on AD risk had positive associations and three were statistically significant, with odds ratios that ranged from 2.4-5.0 (77). Two of these studies demonstrated a synergistic effect with a two-fold increased risk of AD in individuals with T2DM who were  $\epsilon$ 4 carriers compared to non-carriers (78, 79). While one study demonstrated a negative association between T2DM and APOE  $\epsilon$ 4, carrier status was only provided for 59% of its subjects (80). Overall, these findings demonstrate that  $\epsilon$ 4 carriers with T2DM may have an even greater risk of AD and adequate management of T2DM may have particular importance for this population for the purposes of AD prevention.



## Hyperlipidemia

Hyperlipidemia has been associated with an increased risk of AD (72, 81). For example, one study evaluated the impact of midlife hyperlipidemia on the development of AD three decades later and showed that the hazard ratio for AD was 1.23 for borderline high cholesterol (200-239 mg/dl) and 1.57 for high cholesterol ( $\geq$  240 mg/dl) (81). APOE  $\epsilon$ 4 carrier status is associated with higher levels of total cholesterol and LDL cholesterol (82–84) and lower levels of HDL cholesterol compared to non-carriers (82). However, the risk of hyperlipidemia on incident AD may not be the same for  $\epsilon$ 4 carriers and non-carriers. In one study, hyperlipidemia doubled the risk of dementia in  $\epsilon$ 4 non-carriers but was not associated with an increased risk in  $\epsilon$ 4 carriers (85). Other studies have similarly shown that increasing levels of total cholesterol (86, 87) and LDL (87) increased the risk of AD in non-carriers but not in carriers. This suggests that managing hyperlipidemia, while important for improving cardiovascular risk for all patients, may be particularly important for  $\epsilon$ 4 non-carriers for AD prevention.

## Other APOE-Related Considerations

### Sex

There are established differences in the effects of APOE  $\epsilon$ 4 carrier status depending on male or female sex (88). One study showed that non-impaired women who were  $\epsilon$ 4 carriers had almost double the risk of converting to MCI or AD compared to non-carriers, while men who were carriers had only slightly higher rates of conversion (89). A neuroimaging study using FDG-PET showed that women who were  $\epsilon$ 4 carriers had significantly more brain hypometabolism and cortical thinning compared to non-carriers, while the difference between  $\epsilon$ 4 carriers and non-carriers in men was much less substantial (90). However, recent evidence suggests that  $\epsilon$ 4 carrier status may confer the greatest risk for women between the ages of 65-75, and may not confer additional risk compared to men outside of that age bracket (91). Therefore, it is important to consider sex differences when evaluating for AD risk, and additional research may help to elucidate the multi-factorial relationship seen among sex,  $\epsilon$ 4 carrier status, age, and other factors such as menopause.

### Genotype Disclosure

The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) trial was the first RCT to evaluate the impact that disclosure of APOE  $\epsilon$ 4 carrier status had on behavioral change in cognitively normal individuals (92). The researchers found that individuals who learned they were  $\epsilon$ 4 carriers reported more behavioral changes related to diet, exercise, medications, and vitamins compared to those who learned they were non-carriers. In addition, the Food4Me trial demonstrated that  $\epsilon$ 4 non-carriers informed about their carrier status reduced SFA intake less than non-carriers who were not informed (83). These studies demonstrate that the act of disclosing  $\epsilon$ 4 carrier status, as well as non-carrier status, may affect behavior and play a role in commitment to interventions, which is critical for AD prevention success. While APOE  $\epsilon$ 4 carrier status is a sensitive topic that requires a collaborative discussion between patient and treating clinician, in cases deemed clinically appropriate by both parties, disclosing this information may be a beneficial way to encourage behavioral change.

## Conclusion and Future Directions

This review indicates that prevention strategies targeted to APOE carrier status may hold a great deal of promise. Various findings demonstrate that optimizing physical activity, cognitive engagement, alcohol consumption and tobacco use are critical steps toward AD prevention, especially in  $\epsilon 4$  carriers. Dietary changes also hold substantial importance for AD prevention, with specific emphasis on different aspects of diet in carriers versus non-carriers. Evidence suggests that supplementation with n-3 PUFAs is especially important for  $\epsilon 4$  carriers, whereas there is a non-linear relationship between vitamin D and cognitive functioning, and more evidence is required to determine the optimal range for AD prevention. Further research into pharmaceutical targets for AD prevention is also critical, and new clinical trials such as the Generation Studies may help to clarify the role of  $\epsilon 4$  carrier status on pharmaceutical-based prevention interventions.

In addition, the management of hypertension and T2DM may warrant special attention in  $\epsilon 4$  carriers for the purposes of AD prevention, while the management of hyperlipidemia may warrant special attention in non-carriers. Defining specific treatment goals for these comorbidities, as well as investigation into other comorbidities should also be explored in the future. While sex is a non-modifiable risk factor, it is important to be aware of the different risks associated with  $\epsilon 4$  carrier status for men and women in order to optimize AD prevention strategies. Finally, the use of genotype disclosure for consenting patients may promote behavioral change and compliance with prevention recommendations although further study is warranted to determine whether this leads to better outcomes.

As genotyping for APOE  $\epsilon 4$  and other genetic risk factors becomes more widely available, both commercially and in the healthcare setting, its role in clinical care will become more important (93). New technological innovations and tracking devices that facilitate monitoring responses to interventions for both patients and clinicians will further aid in developing effective AD prevention approaches (93). In light of these advances and potential benefits of targeted interventions for  $\epsilon 4$  carriers, inclusion of APOE  $\epsilon 4$  carrier status in AD prevention strategies is likely to be of greater importance in the future.

## Acknowledgments

*Funding:* This research was funded by philanthropic support by the Zuckerman Family Foundation, Women's Alzheimer's Movement, David G. Kabiller Charitable Foundation (In Memory of Adele Rubin Tunick and In Memory of Kaisu Ilmanen), Rimora Foundation, the Washkowitz Family in Memory of Alan Washkowitz, proceeds from the Annual Memories for Mary fundraiser organized by Mr. David Twardock, and contributions from grateful patients of the Alzheimer's Prevention Clinic, Weill Cornell Memory Disorders Program; Grant funding by the Weill Cornell Medicine Clinical and Translational Science Center (NIH/NCATS #UL1TR002384), and NIH PO1AG026572.

## References

1. Mayeux R and Stern Y, Epidemiology of Alzheimer disease. *Cold Spring Harb Perspect Med*, 2012 2(8).
2. Sperling RA, et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*, 2011 7(3): p. 280–92. [PubMed: 21514248]

3. Livingston G, et al., Dementia prevention, intervention, and care. *Lancet*, 2017 390(10113): p. 2673–2734. [PubMed: 28735855]
4. Burke JR and Roses AD, Genetics of Alzheimer's disease. *Int J Neurol*, 1991 25-26: p. 41–51. [PubMed: 11980062]
5. Mahley RW, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*, 1988 240(4852): p. 622–30. [PubMed: 3283935]
6. Corder EH, et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*, 1993 261(5123): p. 921–3. [PubMed: 8346443]
7. Talbot C, et al., Protection against Alzheimer's disease with apoE epsilon 2. *Lancet*, 1994 343(8910): p. 1432–3.
8. Farrer LA, et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama*, 1997 278(16): p. 1349–56. [PubMed: 9343467]
9. Sunderland T, et al., Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biol Psychiatry*, 2004 56(9): p. 670–6. [PubMed: 15522251]
10. Liang KY, et al., Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. *Ann Neurol*, 2010 68(3): p. 311–8. [PubMed: 20818789]
11. Morris JC, et al., APOE Predicts A $\beta$  but not Tau Alzheimer's Pathology in Cognitively Normal Aging. *Ann Neurol*, 2010 67(1): p. 122–31. [PubMed: 20186853]
12. Head D, et al., Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. *Arch Neurol*, 2012 69(5): p. 636–43. [PubMed: 22232206]
13. Kamboh MI, Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. *Hum Biol*, 1995 67(2): p. 195–215. [PubMed: 7729825]
14. Kivipelto M, et al., The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. *Alzheimers Dement*, 2013 9(6): p. 657–65. [PubMed: 23332672]
15. Rosenberg A, et al., Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. *Alzheimers Dement*, 2018 14(3): p. 263–270. [PubMed: 29055814]
16. Solomon A, et al., Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. *JAMA Neurol*, 2018.
17. Hillman CH, et al., Physical activity and cognitive function in a cross-section of younger and older community-dwelling individuals. *Health Psychol*, 2006 25(6): p. 678–87. [PubMed: 17100496]
18. Law LL, et al., Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. *Alzheimers Dement (Amst)*, 2018 10: p. 188–195. [PubMed: 29527551]
19. Hamer M and Chida Y, Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med*, 2009 39(1): p. 3–11. [PubMed: 18570697]
20. Kivipelto M, et al., Apolipoprotein E e4 magnifies lifestyle risks for dementia: a population-based study. *J Cell Mol Med*, 2008 12(6b): p. 2762–71. [PubMed: 18318693]
21. Etnier JL, et al., Cognitive performance in older women relative to ApoEepsilon4 genotype and aerobic fitness. *Med Sci Sports Exerc*, 2007 39(1): p. 199–207. [PubMed: 17218903]
22. Brown BM, et al., Physical activity and amyloid- $\beta$  plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. *Molecular Psychiatry*, 2012 18(8): p. 875. [PubMed: 22889922]
23. Smith JC, et al., Interactive Effects of Physical Activity and APOE-e4 on BOLD Semantic Memory Activation in Healthy Elders. *Neuroimage*, 2011 54(1): p. 635–44. [PubMed: 20691792]
24. Lautenschlager NT, et al., Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *Jama*, 2008 300(9): p. 1027–37. [PubMed: 18768414]

25. Almeida OP, et al., Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. *Addiction*, 2002 97(1): p. 15–28. [PubMed: 11895267]
26. Durazzo TC, Mattsson N, and Weiner MW, Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. *Nicotine Tob Res*, 2016 18(2): p. 204–11. [PubMed: 25847292]
27. Garcia AM, Ramon-Bou N, and Porta M, Isolated and joint effects of tobacco and alcohol consumption on risk of Alzheimer's disease. *J Alzheimers Dis*, 2010 20(2): p. 577–86. [PubMed: 20164550]
28. Anstey KJ, Mack HA, and Cherbuin N, Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. *Am J Geriatr Psychiatry*, 2009 17(7): p. 542–55. [PubMed: 19546653]
29. Mukamal KJ, et al., Prospective study of alcohol consumption and risk of dementia in older adults. *Jama*, 2003 289(11): p. 1405–13. [PubMed: 12636463]
30. Luchsinger JA, et al., Alcohol intake and risk of dementia. *J Am Geriatr Soc*, 2004 52(4): p. 540–6. [PubMed: 15066068]
31. Downer B, Zanjani F, and Fardo DW, The Relationship Between Midlife and Late Life Alcohol Consumption, APOE  $\epsilon$ 4 and the Decline in Learning and Memory Among Older Adults, in *Alcohol Alcohol*. 2014 p. 17–22.
32. Anttila T, et al., Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. *Bmj*, 2004 329(7465): p. 539. [PubMed: 15304383]
33. Krell-Roesch J, et al., Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE  $\epsilon$ 4 Genotype. *JAMA Neurology*, 2018 74(3): p. 332–338.
34. Wilson RS, et al., Cognitive activity and incident AD in a population-based sample of older persons. *Neurology*, 2002 59(12): p. 1910–4. [PubMed: 12499482]
35. Wilson RS, et al., Participation in cognitively stimulating activities and risk of incident Alzheimer disease. *Jama*, 2002 287(6): p. 742–8. [PubMed: 11851541]
36. Niti M, et al., Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. *Int Psychogeriatr*, 2008 20(2): p. 237–51. [PubMed: 18190728]
37. Carlson MC, et al., Midlife activity predicts risk of dementia in older male twin pairs. *Alzheimers Dement*, 2008 4(5): p. 324–31. [PubMed: 18790459]
38. Wirth M, et al., Gene–Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden, in *J Neurosci*. 2014 p. 8612–7. [PubMed: 24948815]
39. Woodard JL, et al., Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. *Curr Alzheimer Res*, 2012 9(4): p. 436–46. [PubMed: 22272622]
40. Mosconi L, et al., Mediterranean Diet and Magnetic Resonance Imaging-Assessed Brain Atrophy in Cognitively Normal Individuals at Risk for Alzheimer's Disease. *J Prev Alzheimers Dis*, 2014 1(1): p. 23–32. [PubMed: 25237654]
41. Singh B, et al., Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis*, 2014 39(2): p. 271–82. [PubMed: 24164735]
42. Martinez-Lapiscina EH, et al., Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial. *Genes Nutr*, 2014 9(3): p. 393. [PubMed: 24643340]
43. Hill E, et al., Adherence to the Mediterranean Diet Is not Related to Beta-Amyloid Deposition: Data from the Women's Healthy Ageing Project. *J Prev Alzheimers Dis*, 2018 5(2): p. 137–141. [PubMed: 29616707]
44. Eskelinen MH, et al., Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. *Int J Geriatr Psychiatry*, 2008 23(7): p. 741–7. [PubMed: 18188871]

45. Laitinen MH, et al., Fat Intake at Midlife and Risk of Dementia and Alzheimer's Disease: A Population-Based Study. *Dementia and Geriatric Cognitive Disorders*, 2018 22(1): p. 99–107.
46. Hanson AJ, et al., Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E varepsilon4 Carriers and Adults with Mild Cognitive Impairment. *J Alzheimers Dis*, 2015 48(1): p. 205–18. [PubMed: 26401941]
47. APOE Genotype and Diet Influences on Alzheimer's Biomarkers - Full Text View - [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT03070535). 2018 [cited 2018 June]; Available from: <https://clinicaltrials.gov/ct2/show/NCT03070535>.
48. Kulzow N, et al., Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults. *J Alzheimers Dis*, 2016 51(3): p. 713–25. [PubMed: 26890759]
49. Yassine HN, et al., Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. *JAMA Neurology*, 2018 74(3): p. 339–347.
50. Stonehouse W, et al., DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. *Am J Clin Nutr*, 2013 97(5): p. 1134–43. [PubMed: 23515006]
51. Vellas B, Voisin T, Dufouil C, et al. MAPT (Multi-Domain Alzheimer's Prevention Trial): clinical biomarkers, results and lessons for the future [abstract OC33]. *J Prev Alzheimers Dis*. 2015;2(4): 292.
52. van de Rest O, et al., Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. *Neurology*, 2008 71(6): p. 430–8. [PubMed: 18678826]
53. Huang TL, et al., Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. *Neurology*, 2005 65(9): p. 1409–14. [PubMed: 16275829]
54. Quinn JF, et al., Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *Jama*, 2010 304(17): p. 1903–11. [PubMed: 21045096]
55. Salem N, Vandal M, and Calon F, The benefit of docosahexaenoic acid for the adult brain in aging and dementia. *Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)*, 2015 92: p. 15–22.
56. Anil E, The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype. *Proc Nutr Soc*, 2007 66(1): p. 60–8. [PubMed: 17343773]
57. Olano-Martin E, et al., Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. *Atherosclerosis*, 2010 209(1): p. 104–10. [PubMed: 19748619]
58. Etgen T, et al., Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. *Dement Geriatr Cogn Disord*, 2012 33(5): p. 297–305. [PubMed: 22759681]
59. Maddock J, et al., 25-Hydroxyvitamin D and cognitive performance in midlife. *Br J Nutr*, 2014 111(5): p. 904–14. [PubMed: 24135155]
60. Maddock J, et al., 25-Hydroxyvitamin D, APOE ε4 genotype and cognitive function: findings from the 1958 British birth cohort. *European journal of clinical nutrition*, 2015 69(4): p. 505–508. [PubMed: 25293430]
61. Guo Z, et al., Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication? *Am J Epidemiol*, 2001 153(3): p. 225–31. [PubMed: 11157409]
62. Szekely CA, et al., NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. *Neurology*, 2008 70(1): p. 17–24. [PubMed: 18003940]
63. Imbimbo BP, Solfrizzi V, and Panza F, Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? *Front Aging Neurosci*, 2010 2.
64. Drye LT and Zandi PP, Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT), in *Dement Geriatr Cogn Dis Extra*. 2012 p. 304–11. [PubMed: 22962554]
65. There's No Tomorrow for TOMMORROW | ALZFORUM. 2018; Available from: <https://www.alzforum.org/news/research-news/theres-no-tomorrow-tommorrow>.

66. A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease - Full Text View - [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT02565511). 2018 [cited 2018 June]; Available from: <https://clinicaltrials.gov/ct2/show/NCT02565511>.
67. Haan MN, et al., The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. *Jama*, 1999 282(1): p. 40–6. [PubMed: 10404910]
68. Gabin JM, et al., Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study. *Alzheimers Res Ther*, 2017 9(1): p. 37. [PubMed: 28569205]
69. Morris MC, et al., Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. *Arch Neurol*, 2001 58(10): p. 1640–6. [PubMed: 11594923]
70. Skoog I, et al., 15-year longitudinal study of blood pressure and dementia. *Lancet*, 1996 347(9009): p. 1141–5. [PubMed: 8609748]
71. Qiu C, et al., Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. *Neurology*, 2003 61(5): p. 655–60. [PubMed: 12963757]
72. Kivipelto M, et al., Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *Bmj*, 2001 322(7300): p. 1447–51. [PubMed: 11408299]
73. Launer LJ, et al., Midlife blood pressure and dementia: the Honolulu-Asia aging study. *Neurobiol Aging*, 2000 21(1): p. 49–55. [PubMed: 10794848]
74. Peila R, et al., Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. *Stroke*, 2001 32(12): p. 2882–9. [PubMed: 11739991]
75. Rodrigue KM, et al., Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. *JAMA Neurol*, 2013 70(5): p. 600–6. [PubMed: 23553344]
76. de Nazareth AM, Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. *Dement Neuropsychol*, 2017 11(2): p. 105–13. [PubMed: 29213501]
77. Vagelatos NT and Eslick GD, Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. *Epidemiol Rev*, 2013 35: p. 152–60. [PubMed: 23314404]
78. Irie F, et al., Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. *Arch Neurol*, 2008 65(1): p. 89–93. [PubMed: 18195144]
79. Peila R, Rodriguez BL, and Launer LJ, Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. *Diabetes*, 2002 51(4): p. 1256–62. [PubMed: 11916953]
80. Borenstein AR, et al., Developmental and vascular risk factors for Alzheimer's disease. *Neurobiol Aging*, 2005 26(3): p. 325–34. [PubMed: 15639310]
81. Solomon A, et al., Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. *Dement Geriatr Cogn Disord*, 2009 28(1): p. 75–80. [PubMed: 19648749]
82. Dallongeville J, Lussier-Cacan S, and Davignon J, Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. *J Lipid Res*, 1992 33(4): p. 447–54. [PubMed: 1388198]
83. Fallaize R, et al., The effect of the apolipoprotein E genotype on response to personalized dietary advice intervention: findings from the Food4Me randomized controlled trial. *Am J Clin Nutr*, 2016 104(3): p. 827–36. [PubMed: 27510539]
84. Khan TA, et al., Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals, in *Int J Epidemiol*. 2013 p. 475–92. [PubMed: 23569189]
85. Dufouil C, et al., APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. *Neurology*, 2005 64(9): p. 1531–8. [PubMed: 15883313]
86. Evans RM, et al., Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. *Neurology*, 2000 54(1): p. 240–2. [PubMed: 10636159]

87. Hall K, et al., Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba. *Neurology*, 2006 66(2): p. 223–7. [PubMed: 16434658]
88. Payami H, et al., Alzheimer’s disease, apolipoprotein E4, and gender. *Jama*, 1994 271(17): p. 1316–7. [PubMed: 8158809]
89. Altmann A, et al., Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann Neurol*, 2014 75(4): p. 563–73. [PubMed: 24623176]
90. Sampedro F, et al., APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. *Oncotarget*, 2015 6(29): p. 26663–74. [PubMed: 26397226]
91. Neu SC, et al., Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. *JAMA Neurol*, 2017 74(10): p. 1178–1189. [PubMed: 28846757]
92. Chao S, et al., Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. *Alzheimer Dis Assoc Disord*, 2008 22(1): p. 94–7. [PubMed: 18317253]
93. Tung JY, Shaw RJ, Hagenkord JM, Hackmann M, Muller M, Beachy SH, Pratt VM, Terry SF, Cashion AK, and Ginsburg GS. 2018 Accelerating precision health by applying the lessons learned from direct-to-consumer genomics to digital health technologies NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC <https://nam.edu/accelerating-precision-health-by-applying-the-lessons-learned-from-direct-to-consumer-genomics-to-digital-health-technologies>.